Literature DB >> 28082458

Developmental Role of Macrophage Cannabinoid-1 Receptor Signaling in Type 2 Diabetes.

Tony Jourdan1, Gergő Szanda2, Resat Cinar2, Grzegorz Godlewski2, David J Holovac2, Joshua K Park2, Sarah Nicoloro3, Yuefei Shen3, Jie Liu2, Avi Z Rosenberg4,5, Ziyi Liu2, Michael P Czech3, George Kunos1.   

Abstract

Islet inflammation promotes β-cell loss and type 2 diabetes (T2D), a process replicated in Zucker Diabetic Fatty (ZDF) rats in which β-cell loss has been linked to cannabinoid-1 receptor (CB1R)-induced proinflammatory signaling in macrophages infiltrating pancreatic islets. Here, we analyzed CB1R signaling in macrophages and its developmental role in T2D. ZDF rats with global deletion of CB1R are protected from β-cell loss, hyperglycemia, and nephropathy that are present in ZDF littermates. Adoptive transfer of CB1R-/- bone marrow to ZDF rats also prevents β-cell loss and hyperglycemia but not nephropathy. ZDF islets contain elevated levels of CB1R, interleukin-1β, tumor necrosis factor-α, the chemokine CCL2, and interferon regulatory factor-5 (IRF5), a marker of inflammatory macrophage polarization. In primary cultured rodent and human macrophages, CB1R activation increased Irf5 expression, whereas knockdown of Irf5 blunted CB1R-induced secretion of inflammatory cytokines without affecting CCL2 expression, which was p38MAPKα dependent. Macrophage-specific in vivo knockdown of Irf5 protected ZDF rats from β-cell loss and hyperglycemia. Thus, IRF5 is a crucial downstream mediator of diabetogenic CB1R signaling in macrophages and a potential therapeutic target.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28082458      PMCID: PMC5360301          DOI: 10.2337/db16-1199

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  45 in total

Review 1.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

2.  IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction.

Authors:  Clara Westwell-Roper; Derek L Dai; Galina Soukhatcheva; Kathryn J Potter; Nico van Rooijen; Jan A Ehses; C Bruce Verchere
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

3.  Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation.

Authors:  Lorenzo Piemonti; Biagio Eugenio Leone; Rita Nano; Alessandra Saccani; Paolo Monti; Paola Maffi; Giancarlo Bianchi; Antonio Sica; Giuseppe Peri; Raffaella Melzi; Luca Aldrighetti; Antonio Secchi; Valerio Di Carlo; Paola Allavena; Federico Bertuzzi
Journal:  Diabetes       Date:  2002-01       Impact factor: 9.461

4.  IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses.

Authors:  Thomas Krausgruber; Katrina Blazek; Tim Smallie; Saba Alzabin; Helen Lockstone; Natasha Sahgal; Tracy Hussell; Marc Feldmann; Irina A Udalova
Journal:  Nat Immunol       Date:  2011-01-16       Impact factor: 25.606

5.  Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes.

Authors:  B J Barnes; P A Moore; P M Pitha
Journal:  J Biol Chem       Date:  2001-04-12       Impact factor: 5.157

6.  Glucan particles for selective delivery of siRNA to phagocytic cells in mice.

Authors:  Gregory J Tesz; Myriam Aouadi; Matthieu Prot; Sarah M Nicoloro; Emilie Boutet; Shinya U Amano; Anca Goller; Mengxi Wang; Chang-An Guo; William E Salomon; Joseph V Virbasius; Rebecca A Baum; Mark J O'Connor; Ernesto Soto; Gary R Ostroff; Michael P Czech
Journal:  Biochem J       Date:  2011-06-01       Impact factor: 3.857

7.  Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation.

Authors:  Kosei Eguchi; Ichiro Manabe; Yumiko Oishi-Tanaka; Mitsuru Ohsugi; Nozomu Kono; Fusa Ogata; Nobuhiro Yagi; Umeharu Ohto; Masao Kimoto; Kensuke Miyake; Kazuyuki Tobe; Hiroyuki Arai; Takashi Kadowaki; Ryozo Nagai
Journal:  Cell Metab       Date:  2012-03-29       Impact factor: 27.287

8.  Selective inhibition of 12-lipoxygenase protects islets and beta cells from inflammatory cytokine-mediated beta cell dysfunction.

Authors:  David A Taylor-Fishwick; Jessica Weaver; Lindsey Glenn; Norine Kuhn; Ganesha Rai; Ajit Jadhav; Anton Simeonov; Angela Dudda; Dieter Schmoll; Theodore R Holman; David J Maloney; Jerry L Nadler
Journal:  Diabetologia       Date:  2014-11-23       Impact factor: 10.122

9.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Authors:  André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

Review 10.  The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes.

Authors:  S E Kahn
Journal:  Diabetologia       Date:  2003-01-11       Impact factor: 10.122

View more
  17 in total

1.  Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Resat Cinar; Bernadette R Gochuico; Malliga R Iyer; Tony Jourdan; Tadafumi Yokoyama; Joshua K Park; Nathan J Coffey; Hadass Pri-Chen; Gergő Szanda; Ziyi Liu; Ken Mackie; William A Gahl; George Kunos
Journal:  JCI Insight       Date:  2017-04-20

2.  Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy.

Authors:  Liad Hinden; Shiran Udi; Adi Drori; Asaad Gammal; Alina Nemirovski; Rivka Hadar; Saja Baraghithy; Anna Permyakova; Matan Geron; Merav Cohen; Sabina Tsytkin-Kirschenzweig; Yael Riahi; Gil Leibowitz; Yaakov Nahmias; Avi Priel; Joseph Tam
Journal:  J Am Soc Nephrol       Date:  2017-10-13       Impact factor: 10.121

3.  Inhibition of hsa_circ_0002570 suppresses high-glucose-induced angiogenesis and inflammation in retinal microvascular endothelial cells through miR-1243/angiomotin axis.

Authors:  Guodan Liu; Shifeng Zhou; Xinge Li; Xuchen Ding; Miao Tian
Journal:  Cell Stress Chaperones       Date:  2020-04-21       Impact factor: 3.667

Review 4.  Cannabinoid Receptors in Diabetic Kidney Disease.

Authors:  F Barutta; R Mastrocola; S Bellini; G Bruno; Gabriella Gruden
Journal:  Curr Diab Rep       Date:  2018-02-05       Impact factor: 4.810

Review 5.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

Review 6.  Endocannabinoids in the Islets of Langerhans: the ugly, the bad, and the good facts.

Authors:  Isabel González-Mariscal; Josephine M Egan
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-04-06       Impact factor: 4.310

Review 7.  The Neuroimmunology of Chronic Pain: From Rodents to Humans.

Authors:  Peter M Grace; Vivianne L Tawfik; Camilla I Svensson; Michael D Burton; Marco L Loggia; Mark R Hutchinson
Journal:  J Neurosci       Date:  2020-11-25       Impact factor: 6.167

Review 8.  Endocannabinoids in immune regulation and immunopathologies.

Authors:  Oindrila Rahaman; Dipyaman Ganguly
Journal:  Immunology       Date:  2021-07-08       Impact factor: 7.215

9.  Decreasing CB1 receptor signaling in Kupffer cells improves insulin sensitivity in obese mice.

Authors:  Tony Jourdan; Sarah M Nicoloro; Zhou Zhou; Yuefei Shen; Jie Liu; Nathan J Coffey; Resat Cinar; Grzegorz Godlewski; Bin Gao; Myriam Aouadi; Michael P Czech; George Kunos
Journal:  Mol Metab       Date:  2017-09-01       Impact factor: 7.422

10.  Signaling through the type 2 cannabinoid receptor regulates the severity of acute and chronic graft-versus-host disease.

Authors:  Cheng Yin Yuan; Vivian Zhou; Garrett Sauber; Todd Stollenwerk; Richard Komorowski; Alicia López; Rosa María Tolón; Julian Romero; Cecilia J Hillard; William R Drobyski
Journal:  Blood       Date:  2021-03-04       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.